In this revealing episode, we welcome Dr. Niculescu, a leading figure in the field of psychiatry and molecular genetics, to discuss his transformative research in anxiety disorders. Despite their increasing prevalence and the significant impact they have on individuals' lives, anxiety disorders often remain underdiagnosed and inadequately treated, leading to serious adverse life events and potential addictions.
Dr. Niculescu takes us on a journey through his groundbreaking approach to discovering blood biomarkers for anxiety. This four-step process includes a longitudinal within-subject design to identify gene expression changes associated with anxiety states, a Convergent Functional Genomics approach to prioritize biomarkers, independent cohort validation, and testing of biomarkers' clinical utility.
Through this comprehensive approach, the research revealed a set of biomarkers that demonstrate promising accuracy, especially in women. Dr. Niculescu shares how these biomarkers, including GAD1, NTRK3, ADRA2A, FZD10, GRK4, and SLC6A4, can target existing drugs, offering the potential to match patients to medications and monitor treatment response. Beyond this, the study identified drugs that could be repurposed for anxiety treatment, including estradiol, pirenperone, loperamide, and disopyramide.
With the urgent need for more precise and personalized approaches to managing anxiety, Dr. Niculescu's research opens up new avenues for diagnosis and treatment. This episode promises to be a fascinating journey into the heart of psychiatry and molecular genetics.
Dr. Niculescu, Anxiety Disorders, Blood Biomarkers, Gene Expression, Convergent Functional Genomics, Clinical Validation, GAD1, NTRK3, ADRA2A, FZD10, GRK4, SLC6A4, Personalized Medicine, Drug Repurposing, Psychiatry, Molecular Genetics.
Le-Niculescu, et al. Towards precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. 2023. https://doi.org/10.1038/s41380-023-01998-0